Delivery Order SPE2DB20D3505-SPE2DB23FU4P9
- Not listed
- This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampuls, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $7,941.03 and an ultimate completion date of October 12, 2023. It is a Firm Fixed Price Delivery Order contract, without any set-aside designation. Amerisourcebergen...
- This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for a ceiling value of $4,102.27. The award, which has a firm fixed price pricing type, was made on May 4, 2022, with an ultimate completion date of May 5, 2022. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has a ceiling value of $20,964.92 and a completion date of May 27, 2022. This is a delivery order contract with a firm fixed price pricing type. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp is a...
- This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor that serves federal government agencies. The contract, valued at $4,604.30, is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampuls. The contract, valued at $32,686.58, is a firm-fixed-price delivery order with an ultimate completion date of January 19, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The U.S. Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL. The $2,410.99 firm fixed-price contract has a completion date of March 22, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA for a wide range of pharmaceutical products and medical supplies to support the Department of Defense worldwide. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampul 2.5ml. The contract has a ceiling value of $5,344.56 and an ultimate completion date of April 13, 2022. The contract is a Delivery Order under a Firm Fixed Price pricing type, and there was no set-aside used. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization registered...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $14,881.52, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a pharmaceutical product. This is a firm fixed-price delivery order contract with an ultimate completion date of May 22, 2023. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has a ceiling value of $31,801.68 and is a firm-fixed-price delivery order with a completion date of September 13, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award is for the delivery of Pulmozyme, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $13,812.90, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order with a completion date of March 27, 2023. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB23FU4P9Delivery Order
This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $4,604.30 and is a firm fixed-price delivery order with a completion date of July 26, 2023. The contract was not set aside for any specific business type. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that supplies a wide range of medical products, including specialty medications, generic drugs, and medical devices, to various federal agencies. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for delivering essential pharmaceutical and medical supplies to support military healthcare programs globally. Additionally, Amerisourcebergen Drug Corp maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 7/25/23 |